All In Biotech

NDA 050547 · Sterimax

Claforan

Cefotaxime Sodium · Injection

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Mar 11, 1981

Approved uses

2

Original approval plus efficacy supplements

Registered trials

214

60 Phase 3, 18 recruiting

FAERS reports

5,624

5,523 serious, 1,079 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 14, 2026.

INDICATIONS AND USAGE Treatment CLAFORAN is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae , Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species , Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections. Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 27, 1996 Supplement 42 · Efficacy
  • Mar 11, 1981 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
  • CLAFORAN · CEFOTAXIME SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription
  • CLAFORAN · CEFOTAXIME SODIUM EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • CLAFORAN · CEFOTAXIME SODIUM EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
  • CLAFORAN · CEFOTAXIME SODIUM EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Cefotaxime" as an intervention, any sponsor and status, largest first.

All 214 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia406
  • drug ineffective381
  • off label use349
  • drug reaction with eosinophilia and systemic symptoms276
  • acute kidney injury256
  • thrombocytopenia219
  • neutropenia197
  • rash182
  • toxic epidermal necrolysis177
  • sepsis174
  • condition aggravated169
  • diarrhoea164

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004101
2005111
200681
2007133
200897
2009138
201094
2011190
2012198
2013175
2014186
2015228
2016228
2017249
2018395
2019448
2020617
2021473
2022399
2023373
2024316
2025243
2026148

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 594 on PubMed

Sponsor: Sterimax

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.